Making Sense of Today’s 340B Policy Entanglements As covered entities face rising healthcare costs, reimbursement cuts, and uncompensated care, the Federal 340B Drug Pricing Program continues to be an important source of funding for vital patient care. Get updates on how the 340B program solutions can help providers manage reporting compliance across an increasingly complex pharmacy supply chain, while capturing drug cost savings. Guest Expert: Ted Slafsky, Publisher and CEO, 340B Report    Host: Ken Perez, Vice President, Healthcare Policy and Government Affairs, Omnicell See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices